{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706269,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00280-021-04257-7","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T11:08:22Z","timestamp":1617966502000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-3602","authenticated-orcid":false,"given":"Mohamed","family":"A. Mahrous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"A. El-Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"A. Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"9","key":"4257_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00520-006-0186-7","volume":"15","author":"K Jordan","year":"2007","unstructured":"Jordan K et al (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15(9):1023\u20131033","journal-title":"Support Care Cancer"},{"issue":"27","key":"4257_CR2","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2011.39.8123","volume":"30","author":"JA Roscoe","year":"2012","unstructured":"Roscoe JA et al (2012) Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30(27):3389\u20133395","journal-title":"J Clin Oncol"},{"issue":"2","key":"4257_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115\u2013124","journal-title":"Lancet Oncol"},{"issue":"9","key":"4257_CR4","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1007\/s00520-016-3203-5","volume":"24","author":"K Kubota","year":"2016","unstructured":"Kubota K et al (2016) Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer 24(9):4025\u20134033","journal-title":"Support Care Cancer"},{"issue":"5","key":"4257_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro M et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083\u20131088","journal-title":"Ann Oncol"},{"issue":"23","key":"4257_CR6","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482\u20132494","journal-title":"N Engl J Med"},{"issue":"9","key":"4257_CR7","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","volume":"17","author":"RJ Gralla","year":"1999","unstructured":"Gralla RJ et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971\u20132994","journal-title":"J Clin Oncol"},{"issue":"2","key":"4257_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00520-013-1999-9","volume":"22","author":"L Schwartzberg","year":"2014","unstructured":"Schwartzberg L et al (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22(2):469\u2013477","journal-title":"Support Care Cancer"},{"issue":"6","key":"4257_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00520-010-0908-8","volume":"19","author":"TE Botrel","year":"2011","unstructured":"Botrel TE et al (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19(6):823\u2013832","journal-title":"Support Care Cancer"},{"issue":"6","key":"4257_CR10","first-page":"1289","volume":"23","author":"O Geling","year":"2005","unstructured":"Geling O, Eichler H-G (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Syst Re-Eval Clin Evid Drug Cost Implic 23(6):1289\u20131294","journal-title":"Syst Re-Eval Clin Evid Drug Cost Implic"},{"issue":"11","key":"4257_CR11","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/annonc\/mdp195","volume":"20","author":"M Maemondo","year":"2009","unstructured":"Maemondo M et al (2009) A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol 20(11):1860\u20131866","journal-title":"Ann Oncol"},{"issue":"9","key":"4257_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441\u20131449","journal-title":"Ann Oncol"},{"issue":"7","key":"4257_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ et al (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw 15(7):883\u2013893","journal-title":"J Natl Compr Canc Netw"},{"key":"4257_CR14","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1007\/s00520-010-0994-7","volume":"19 Suppl 1","author":"K Jordan","year":"2011","unstructured":"Jordan K et al (2011) Antiemetics in children receiving chemotherapy. MASCC\/ESMO guideline update 2009. Support Care Cancer. 19 Suppl 1:S37-42","journal-title":"Support Care Cancer."},{"issue":"4","key":"4257_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00520-017-3936-9","volume":"26","author":"PJ Hesketh","year":"2018","unstructured":"Hesketh PJ, Palmas M, Nicolas P (2018) Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic. Support Care Cancer 26(4):1151\u20131159","journal-title":"Support Care Cancer"},{"issue":"suppl 5","key":"4257_CR16","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133","journal-title":"Ann Oncol"},{"issue":"12","key":"4257_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JOP.2017.026351","volume":"13","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Bohlke K, Kris MG (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract 13(12):825\u2013830","journal-title":"J Oncol Pract"},{"issue":"12","key":"4257_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","volume":"24","author":"Y Okada","year":"2019","unstructured":"Okada Y et al (2019) One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist 24(12):1593\u20131600","journal-title":"Oncologist"},{"issue":"1","key":"4257_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","volume":"19","author":"L Celio","year":"2019","unstructured":"Celio L et al (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19(1):1268","journal-title":"BMC Cancer"},{"issue":"9","key":"4257_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17512433.2016.1190271","volume":"9","author":"GP Simino","year":"2016","unstructured":"Simino GP et al (2016) Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Expert Rev Clin Pharmacol 9(9):1183\u20131194","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"4257_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1213\/ane.0b013e318172fa74","volume":"107","author":"C Rojas","year":"2008","unstructured":"Rojas C et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107(2):469\u2013478","journal-title":"Anesth Analg"},{"issue":"10","key":"4257_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/iju.12842","volume":"22","author":"H Kitamura","year":"2015","unstructured":"Kitamura H et al (2015) Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine\/cisplatin in urothelial cancer patients. Int J Urol 22(10):911\u2013914","journal-title":"Int J Urol"},{"issue":"12","key":"4257_CR23","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1021\/acschemneuro.6b00132","volume":"7","author":"KL Price","year":"2016","unstructured":"Price KL et al (2016) Palonosetron-5-HT3 receptor interactions as shown by a binding protein cocrystal structure. ACS Chem Neurosci 7(12):1641\u20131646","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"4257_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1124\/jpet.110.166181","volume":"335","author":"C Rojas","year":"2010","unstructured":"Rojas C et al (2010) The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335(2):362\u2013368","journal-title":"J Pharmacol Exp Ther"},{"key":"4257_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/B978-0-323-48110-6.00034-X","volume-title":"Pharmacology and physiology for anesthesia (Second Edition)","author":"ES Zabirowicz","year":"2019","unstructured":"Zabirowicz ES, Gan TJ (2019) 34 - Pharmacology of postoperative nausea and vomiting. In: Hemmings HC, Egan TD (eds) Pharmacology and physiology for anesthesia (Second Edition). Elsevier, Philadelphia, pp 671\u2013692"},{"issue":"8","key":"4257_CR26","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00221-014-4017-7","volume":"232","author":"AG Thomas","year":"2014","unstructured":"Thomas AG et al (2014) Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res 232(8):2637\u20132644","journal-title":"Exp Brain Res"},{"issue":"3","key":"4257_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cam4.373","volume":"4","author":"H Kimura","year":"2015","unstructured":"Kimura H et al (2015) Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Cancer Med 4(3):333\u2013341","journal-title":"Cancer Med"},{"issue":"4","key":"4257_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.pbb.2011.05.025","volume":"99","author":"NA Darmani","year":"2011","unstructured":"Darmani NA et al (2011) Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 99(4):573\u2013579","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"4257_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0014-2999(01)01297-3","volume":"428","author":"M Minami","year":"2001","unstructured":"Minami M et al (2001) Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 428(2):215\u2013220","journal-title":"Eur J Pharmacol"},{"issue":"2\u20133","key":"4257_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejphar.2009.10.002","volume":"626","author":"C Rojas","year":"2010","unstructured":"Rojas C et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626(2\u20133):193\u2013199","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"4257_CR31","first-page":"suppl 6","volume":"94","author":"AA Genazzani","year":"2008","unstructured":"Genazzani AA, Billington RA (2008) Pharmacokinetic and pharmacodynamic features of palonosetron. Tumori 94(2):suppl 6-13","journal-title":"Tumori"},{"issue":"5","key":"4257_CR32","first-page":"617","volume":"40","author":"H Osawa","year":"2013","unstructured":"Osawa H, Goto H, Myojo T (2013) Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute. Gan To Kagaku Ryoho 40(5):617\u2013621","journal-title":"Gan To Kagaku Ryoho"},{"issue":"5","key":"4257_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/1078155219882076","volume":"26","author":"NE Omar","year":"2020","unstructured":"Omar NE et al (2020) Perceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in Qatar. J Oncol Pharm Pract 26(5):1086\u20131096","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"4257_CR34","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27(8):1601\u20131606","journal-title":"Ann Oncol"},{"issue":"8","key":"4257_CR35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.7150\/jca.17102","volume":"8","author":"H Toda","year":"2017","unstructured":"Toda H et al (2017) Antiemetic effectiveness and cost-saving of aprepitant plus granisetron is superior to palonosetron in gastrointestinal cancer patients who received moderately emetogenic chemotherapy. J Cancer 8(8):1371\u20131377","journal-title":"J Cancer"},{"issue":"6","key":"4257_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/1078155216652212","volume":"23","author":"Q Du","year":"2017","unstructured":"Du Q et al (2017) Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of \u201coverall\u201d nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients. J Oncol Pharm Pract 23(6):403\u2013412","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04257-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:04:31Z","timestamp":1621947871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04257-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4257"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04257-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors have no conflicts of interest to declare that they are relevant to this article's content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the ethics committee of Tanta university. The procedures used in this study adhere to the tenets of the Declaration of Helsinki 1964.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Additional informed consent was obtained from all individual participants for identifying information in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}